| Table 1: Pharming Group N.V.'s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, Europe, and Rest of the World......3 |
| Hemophilia A......4 |
| Table 2: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......4 |
| Table 3: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......5 |
| Table 4: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......6 |
| Table 5: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......7 |
| Continuous Prophylaxis......8 |
| Table 6: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......8 |
| Table 7: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......9 |
| Intermittent Prophylaxis......10 |
| Table 8: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......10 |
| Table 9: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......11 |
| Protease Inhibitors......12 |
| Table 10: Hepatitis C Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno Modulator, Polymerase Inhibitor, Protease Inhibitors, and Others* (Includes Ribavirin)......12 |
| Table 11: HIV Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)/ Nucleoside Reverse Transcriptase Inhibitor (NRTI) Fixed Dose Combination (FDC), Nucleoside Reverse Transcriptase Inhibitor (NRTI)/Retroviral Integrase/CYP3A, Nucleoside Reverse Transcriptase Inhibitor (NRTIs), Protease Inhibitors, Retroviral Integrase (IN), and Others* (Includes NNRTIs)......13 |
| Table 12: Protease Inhibitors Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for APTIVUS, KALETRA, PREZISTA, and REYATAZ......14 |
| Table 13: Hepatitis C Virus Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno-Modulator, Polymerase Inhibitor, Protease Inhibitors, Ribavirin, and Others......15 |
| Factor VIII (FVIII)......16 |
| Table 14: Factor VIII (FVIII) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Plasma-Derived (PD FVIII) and Standard r-FVIII (Recombinant FVIII)......16 |
| Table 15: Plasma Derivatives Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value for Albumin, Alpha-1 Proteinase Inhibitor (A1PI), Hyperimmune, Intravenous Immunoglobulin (IVIG), Plasma-Derived Factor VIII (PDFVIII) & Willebrand Factor (WFactor), Polymeric Immunoglobulin Receptor, and Others......17 |
| Table 16: Plasma Market by Product Worldwide (2015) - Percentage Breakdown by Value for Albumin, Factor IX, Factor VIII, Hyperimmunes, Intravenous Immunoglobulin (IVIG), and Others......18 |
| Table 17: Plasma Market by Products (excluding Recombinant Factors) Worldwide (2015) - Percentage Share Breakdown by Value for Albumin, Factor VIII, Intravenous Immunoglobulin (IVIG) and Others......19 |
| Table 18: Plasma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Coagulation Factor IX, Coagulation Factor VIII, Fibrinogen, Human Albumin, Intravenous Immunoglobulin (IVIG), Specific Immunoglobulin and Others......20 |
| Table 19: Plasma Products Consumption by Type in China (2015) - Percentage Share Breakdown by Volume for Albumin, Factor VIII, Hyperimmunes (IM&IV), and Intravenous Immunoglobulin (IVIG)......21 |
| Table 20: Plasma Market by Segment in China (2015) - Percentage Share Breakdown by Value for Alpha-1 proteinase inhibitor (A1PI), Coagulation Factor IX, Coagulation Factor VIII, Fibrinogen, Human Albumin, Immunoglobulin for Intramuscular Injection, Intravenous Immunoglobulin (IVIG), Prothrombin Complex, and Specific Immunoglobulin......22 |
| Table 21: Factor VIII (FVIII) Market by Category in the US (2015) - Percentage Share Breakdown by Volume Sales for Plasma-Derived (PD) FVIII and Standard r-FVIII (Recombinant FVIII)......23 |
| Table 22: Factor VIII (FVIII) Market by Category in the US (2015) - Percentage Share Breakdown by Value Sales for Plasma-Derived (PD FVIII) and Standard r-FVIII (Recombinant FVIII)......24 |
| Table 23: Plasma Products Consumption by Type in the US (2015) - Percentage Share Breakdown by Volume for Albumin, Factor IX (Plasma), Factor VIII, Hyperimmunes (IM&IV), and Intravenous Immunoglobulin (IVIG), and Others......25 |
| Alpha-Glucosidase Inhibitors......26 |
| Table 24: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type‐1 Diabetes, Insulin Type‐2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP‐1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others* (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......26 |
| Table 25: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......27 |
| Table 26: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......28 |
| Haemophilia A......29 |
| Table 27: Market Shares of Leading Haemophilia A Treatment Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value Sales for Baxter International Inc. (Advate), Bayer AG (Kogenate), CSL Behring, LLC (Helixate), Pfizer, Inc. (Refacto) and Others......29 |
| Pancreatic Enzyme......30 |
| Table 28: Market Shares of Leading Pancreatic Enzyme Manufacturers in the US (2015) - Percentage Share Breakdown by Prescriptions for Abbott Laboratories, Alcan Ohler GmbH, Aptalis, Johnson and Johnson, and Other......30 |
| Factor VIII (With Recombinant Factor)......31 |
| Table 29: Market Shares of Leading Factor VIII (Without Recombinant Factor) Companies in China (2014) - Percentage Breakdown by Value for China Biologic Products, Inc., Green Cross Corporation, Hualan Biological Engineering, Inc., and Shanghai RAAS Blood Products Co., Ltd.......31 |
| Table 30: Market Shares of Leading Factor VIII (With Recombinant Factor) Companies in China (2014) - Percentage Breakdown by Value for Bayer AG, China Biologic Products, Inc., Green Cross Corporation, Hualan Biological Engineering, Inc., and Shanghai RAAS Blood Products Co., Ltd.......32 |
| Table 31: Market Shares of Leading Factor VIII Providers in China (2015) - Percentage Breakdown by Value for China Biologic Products, Inc., Green Cross (China) Co., Ltd., Shanghai RAAS Blood Products Co., Ltd., and Others......33 |
| Table 32: Market Shares of Leading Factor VIII Providers in the US (2015) - Percentage Breakdown by Value for Baxter International Inc., CSL Limited, Grifols, S.A., and Kedrion S.p.A......34 |
| Table 33: Pharming Group N.V.'s Sales by Geographic Region Worldwide (2013-2014) in Percentage for United States, Europe and Rest of the World......35 |
